

HOUSE COMMITTEE OF REFERENCE REPORT

Chairman of Committee

April 13, 2017
Date

Committee on Health, Insurance, & Environment.

After consideration on the merits, the Committee recommends the following:

HB17-1318 be amended as follows, and as so amended, be referred to the Committee of the Whole with favorable recommendation:

- 1 Amend printed bill, page 4, line 17, before "NET" insert "AGGREGATE".
- 2 Page 4, lines 22 and 23, strike "WITH THE AGGREGATE COST OF EACH
3 PHARMACEUTICAL" and substitute "SPECIFYING FOR EACH CATEGORY THE
4 TOTAL NUMBER OF PRESCRIPTIONS, THE AGGREGATE GROSS SPENDING, THE
5 AGGREGATE NET SPENDING,".
- 6 Page 5, line 5, strike "AGGREGATE COST," and substitute "GROSS
7 SPENDING, SPECIFYING FOR EACH DRUG CLASS THE TOTAL NUMBER OF
8 PRESCRIPTIONS, THE AGGREGATE GROSS SPENDING, THE AGGREGATE NET
9 SPENDING,".
- 10 Page 5, lines 6 and 7, strike "THE NET COST OF EACH PHARMACEUTICAL ON
11 THE LIST,".
- 12 Page 5, line 27, strike "COST OF A SPECIFIC PHARMACEUTICAL".
- 13 Page 6, strike line 1 and substitute "GROSS SPENDING PER DRUG CLASS,
14 THE AGGREGATE NET SPENDING PER DRUG CLASS, AND THE RANGE OF
15 AGGREGATE GROSS AND NET SPENDING ACROSS THE DRUGS IN A GIVEN
16 CLASS WHEN THERE ARE MORE THAN TWO PHARMACEUTICALS IN THE
17 DRUG".
- 18 Page 6, line 5, strike "CARRIER OR HEALTH BENEFIT PLAN;" and substitute

1 "CARRIER, HEALTH BENEFIT PLAN, OR PRODUCT MANUFACTURER; AND".

2 Page 6, strike lines 6 and 7.

3 Page 6, after line 10 insert:

4 "(III) IN DEVELOPING THE REPORT, THE COMMISSIONER SHALL
5 CONSIDER THE RELATIVE POSITIVE EFFECTS DRUG ADHERENCE HAS ON THE
6 HEALTH OF COLORADANS."

** *** ** *** **